Trial Profile
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Sep 2015
Price :
$35
*
At a glance
- Drugs Eptifibatide (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Adverse reactions
- 16 Sep 2015 New trial record